4771-32-8

Basic information

• Product Name: 4-(chloromethyl)-2-(4-nitrophenyl)-1,3-thiazole
• Synonyms: 4-(chloromethyl)-2-(4-nitrophenyl)-1,3-thiazole;4-(chloromethyl)-2-(4-nitrophenyl)thiazole;MFCD05860576
• CAS NO: 4771-32-8
• Molecular Formula: C₁₀H₇ClN₂O₂S
• Molecular Weight: 254.7
• Mol File: 4771-32-8.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(chloromethyl)-2-(4-nitrophenyl)-1,3-thiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(chloromethyl)-2-(4-nitrophenyl)-1,3-thiazole(4771-32-8)
• EPA Substance Registry System: 4-(chloromethyl)-2-(4-nitrophenyl)-1,3-thiazole(4771-32-8)

Safety Data

• Hazardous Substances Data: 4771-32-8(Hazardous Substances Data)

Upstream product

• 534-07-6 1,3-Dichloroacetone 
• 26060-30-0 4-nitrothiobenzamide 
• 619-72-7 4-nitrobenzonitrile 

Downstream Products

• 4809-93-2 5-chloro-4-chloromethyl-2-(4-nitro-phenyl)-thiazole 
• 4771-36-2 5-bromo-4-chloromethyl-2-(4-nitro-phenyl)-thiazole 
• 36094-01-6 [2-(4-nitro-phenyl)-thiazol-4-yl]-methanol 
• 1589081-28-6 4-amino-6-(benzo[d][1,3]dioxol-5-yl)-2-((2-phenylthiazol-4-yl)methylthio)pyrimidine-5-carbonitrile 
• 52041-99-3 5-bromo-2-(4-nitro-phenyl)-thiazole-4-carboxylic acid 
• 52041-85-7 [5-bromo-2-(4-nitro-phenyl)-thiazol-4-yl]-methanol 
• 52041-95-9 5-bromo-2-(4-nitro-phenyl)-thiazole-4-carbaldehyde 

Relevant articles and documents

Agonists for the adenosine A1 receptor with tunable residence time. a case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines

We report the synthesis and evaluation of previously unreported 4-amino-6-aryl-5-cyano-2-thiopyrimidines as selective human adenosine A 1 receptor (hA1AR) agonists with tunable binding kinetics, this without affecting their nanomolar affinity for the target receptor. They show a very diverse range of kinetic profiles (from 1 min (compound 52) to 1 h (compound 43)), and their structure-affinity relationships (SAR) and structure-kinetics relationships (SKR) were established. When put in perspective with the increasing importance of binding kinetics in drug discovery, these results bring new evidence of the consequences of affinity-only driven selection of drug candidates, that is, the potential elimination of slightly less active compounds that may display preferable binding kinetics.